Compare IMUX & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMUX | QTRX |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.8M | 160.0M |
| IPO Year | 2013 | 2017 |
| Metric | IMUX | QTRX |
|---|---|---|
| Price | $6.88 | $3.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 3 |
| Target Price | ★ $43.09 | $3.00 |
| AVG Volume (30 Days) | 392.9K | ★ 886.3K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $37,632,000.00 |
| Revenue This Year | N/A | $3.55 |
| Revenue Next Year | N/A | $10.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 64.52 |
| 52 Week Low | $0.51 | $2.15 |
| 52 Week High | $17.43 | $8.77 |
| Indicator | IMUX | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 24.48 | 50.07 |
| Support Level | $0.83 | $2.89 |
| Resistance Level | $15.82 | $3.25 |
| Average True Range (ATR) | 0.63 | 0.26 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 0.17 | 19.60 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.